Advertisement GSK, A*STAR to jointly develop new medicines for emerging markets - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

GSK, A*STAR to jointly develop new medicines for emerging markets

GlaxoSmithKline (GSK) and A*STAR's Institute of Chemical Engineering and Sciences (ICES) have collaborated to jointly develop new medicines targeting emerging markets.

The collaboration agreed for a period of five years will focus on developing new evidence based formulations (EBFs) for added patient benefit.

ICES executive director Dr Keith Carpenter said, "Collaborating with GSK, a global leader in pharmaceuticals and healthcare provides an opportunity for us to further our research and deepen our capabilities in formulation science with skilled scientists and technical expertise."

GlaxoSmithKline’s drug candidate selection, optimisation, and product development skill in new formulations in addition to ICES’ expertise in synthesis, formulation and process development will be leveraged in EBFs development.

GSK emerging markets and Asia Pacific R&D vice president Duncan McKay said, "Within GSK’s portfolio of off-patent products, EBFs are an important part of our growth strategy, and our hope is that together with ICES we will create a sustainable, scalable model to meet both specific market conditions and patient requirements."

The organizations believe that the joint partnership will place Singapore as a regional centre for drug development for the emerging markets.

Singapore Economic Development Board biomedical sciences director Kevin Lai said GSK selected Singapore as a strategic partner to develop new evidenced-based drug formulations.

"This is a strong support of Singapore’s scientific talent and capabilities. It also further reinforces Singapore’s offering as the base for companies to generate insights and develop new solutions and market access strategies for the fast growing emerging markets."